GAPDHP23

Across TCGA pan-cancer cohorts, GAPDHP23 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated GAPDHP23 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GAPDHP23 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GAPDHP23 expression acts as an unfavorable survival marker, although some lineages such as ACC and LIHC show a favorable association.

LUAD, BRCA, and UCS are the cancer types where GAPDHP23 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.194	0.427	.001	46	view →
BRCA	OS	Quartile	II,III,IV	0.928	0.967	.003	44	view →
UCS	DFS	Median	IV	0.192	0.776	<.001	36	view →
MESO	DFS	Tertile	II,III,IV	0.224	0.686	.006	24	view →
ACC	DFS	Median	II,III,IV	0.879	0.565	.019	15	view →
TGCT	OS	Tertile	All	0.860	1.000	.001	14	view →
STAD	OS	Tertile	II,III,IV	0.480	0.773	.012	12	view →
THCA	OS	Tertile	IV	0.523	0.924	.001	12	view →
LIHC	DFS	Tertile	All	0.597	0.379	.011	8	view →
ESCA	DFS	Tertile	All	1.000	0.456	.010	7	view →
BLCA	OS	Quartile	III,IV	0.567	0.719	.014	7	view →
SKCM	DFS	Median	III,IV	0.502	0.755	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

GAPDHP23–LUAD (OS)

Open the LUAD breakdown →